Effect of Uric Acid in Animal Models of Ischemic Stroke: A Systematic Review and Meta-analysis

Overview

Journal J Cereb Blood Flow Metab

Publisher Sage Publications

Specialties Cardiology & Vascular Diseases
Endocrinology
Neurology

Date 2020 Nov 19

PMID 33210575

Citations 16

Authors

Alicia Aliena-Valero

Julia Baixauli-Martin

Maria Castello-Ruiz

German Torregrosa

David Hervas

Juan B Salom

Affiliations

Soon will be listed here.

Abstract

Addition of uric acid (UA) to thrombolytic therapy, although safe, showed limited efficacy in improving patients' stroke outcome, despite alleged neuroprotective effects of UA in preclinical research. This systematic review assessed the effects of UA on brain structural and functional outcomes in animal models of ischemic stroke. We searched Medline, Embase and Web of Science to identify 16 and 14 eligible rodent studies for qualitative and quantitative synthesis, respectively. Range of evidence met 10 of a possible 13 STAIR criteria. Median (Q1, Q3) quality score was 7.5 (6, 10) on the CAMARADES 15-item checklist. For each outcome, we used standardised mean difference (SMD) as effect size and random-effects modelling. Meta-analysis showed that UA significantly reduced infarct size (SMD: -1.18; 95% CI [-1.47, -0.88]; < 0.001), blood-brain barrier (BBB) impairment/oedema (SMD: -0.72; 95% CI [-0.97, -0.48]; < 0.001) and neurofunctional deficit (SMD: -0.98; 95% CI [-1.32, -0.63]; < 0.001). Overall, there was low to moderate between-study heterogeneity and sizeable publication bias. In conclusion, published rodent data suggest that UA improves outcome following ischemic stroke by reducing infarct size, improving BBB integrity and ameliorating neurofunctional condition. Specific recommendations are given for further high-quality preclinical research required to better inform clinical research.

Citing Articles

The hazards of chasing subgroups in neutral stroke trials.

Bath P, Howard G, Hacke W Neurol Res Pract. 2025; 7(1):17.

PMID: 40069910 DOI: 10.1186/s42466-025-00369-0.

Role of salvianolic acid B in the treatment of acute ischemic stroke: a systematic review and meta-analysis of animal models.

Wang J, Su P, Wan C, Xu Y, Huang J, Niu J Front Pharmacol. 2025; 15():1479765.

PMID: 39776581 PMC: 11705389. DOI: 10.3389/fphar.2024.1479765.

Targeting uric acid: a promising intervention against oxidative stress and neuroinflammation in neurodegenerative diseases.

Xu L, Li C, Wan T, Sun X, Lin X, Yan D Cell Commun Signal. 2025; 23(1):4.

PMID: 39754256 PMC: 11699683. DOI: 10.1186/s12964-024-01965-4.

Association of Serum Uric Acid to Lymphocyte Ratio with Clinical Outcomes in Cerebral Venous Sinus Thrombosis.

Zhao J, Liu K, Dai Q, Zhang M, Li S, Gao Y J Inflamm Res. 2024; 17:9379-9389.

PMID: 39606636 PMC: 11598599. DOI: 10.2147/JIR.S490407.

Association between uric acid and the risk of hemorrhagic transformation in patients with acute ischemic stroke: a systematic review and meta-analysis.

Qian Y, Li N, Li Y, Tao C, Liu Z, Zhang G Front Neurol. 2024; 15:1378912.

PMID: 39119562 PMC: 11306017. DOI: 10.3389/fneur.2024.1378912.

References

Fisher M, Feuerstein G, Howells D, Hurn P, Kent T, Savitz S . Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009; 40(6):2244-50. PMC: 2888275. DOI: 10.1161/STROKEAHA.108.541128. View

Ma Y, Su N, Chao X, Zhang Y, Zhang L, Han F . Thioredoxin-1 attenuates post-ischemic neuronal apoptosis via reducing oxidative/nitrative stress. Neurochem Int. 2012; 60(5):475-83. DOI: 10.1016/j.neuint.2012.01.029. View

Yu Z, Bruce-Keller A, GOODMAN Y, Mattson M . Uric acid protects neurons against excitotoxic and metabolic insults in cell culture, and against focal ischemic brain injury in vivo. J Neurosci Res. 1998; 53(5):613-25. DOI: 10.1002/(SICI)1097-4547(19980901)53:5<613::AID-JNR11>3.0.CO;2-1. View

Nair A, Jacob S . A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016; 7(2):27-31. PMC: 4804402. DOI: 10.4103/0976-0105.177703. View

Amaro S, Obach V, Cervera A, Urra X, Gomez-Choco M, Planas A . Course of matrix metalloproteinase-9 isoforms after the administration of uric acid in patients with acute stroke: a proof-of-concept study. J Neurol. 2009; 256(4):651-6. DOI: 10.1007/s00415-009-0153-6. View

Peeling J, Corbett D, Del Bigio M, Hudzik T, Campbell T, Palmer G . Rat middle cerebral artery occlusion: correlations between histopathology, T2-weighted magnetic resonance imaging, and behavioral indices. J Stroke Cerebrovasc Dis. 2007; 10(4):166-77. DOI: 10.1053/jscd.2001.26865. View

Schaar K, Brenneman M, Savitz S . Functional assessments in the rodent stroke model. Exp Transl Stroke Med. 2010; 2(1):13. PMC: 2915950. DOI: 10.1186/2040-7378-2-13. View

Gibson C, Gray L, Murphy S, Bath P . Estrogens and experimental ischemic stroke: a systematic review. J Cereb Blood Flow Metab. 2006; 26(9):1103-13. DOI: 10.1038/sj.jcbfm.9600270. View

Vesterinen H, Currie G, Carter S, Mee S, Watzlawick R, Egan K . Systematic review and stratified meta-analysis of the efficacy of RhoA and Rho kinase inhibitors in animal models of ischaemic stroke. Syst Rev. 2013; 2:33. PMC: 3665471. DOI: 10.1186/2046-4053-2-33. View

10.

Onetti Y, Dantas A, Perez B, Cugota R, Chamorro A, Planas A . Middle cerebral artery remodeling following transient brain ischemia is linked to early postischemic hyperemia: a target of uric acid treatment. Am J Physiol Heart Circ Physiol. 2015; 308(8):H862-74. DOI: 10.1152/ajpheart.00001.2015. View

11.

Macleod M, OCollins T, Horky L, Howells D, Donnan G . Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab. 2005; 25(6):713-21. DOI: 10.1038/sj.jcbfm.9600064. View

12.

McCann S, Cramond F, Macleod M, Sena E . Systematic Review and Meta-Analysis of the Efficacy of Interleukin-1 Receptor Antagonist in Animal Models of Stroke: an Update. Transl Stroke Res. 2016; 7(5):395-406. PMC: 5014900. DOI: 10.1007/s12975-016-0489-z. View

13.

Chamorro A, Amaro S, Castellanos M, Segura T, Arenillas J, Marti-Fabregas J . Safety and efficacy of uric acid in patients with acute stroke (URICO-ICTUS): a randomised, double-blind phase 2b/3 trial. Lancet Neurol. 2014; 13(5):453-60. DOI: 10.1016/S1474-4422(14)70054-7. View

14.

Wu X, Lee C, Muzny D, Caskey C . Urate oxidase: primary structure and evolutionary implications. Proc Natl Acad Sci U S A. 1989; 86(23):9412-6. PMC: 298506. DOI: 10.1073/pnas.86.23.9412. View

15.

Chamorro A . Neuroprotectants in the Era of Reperfusion Therapy. J Stroke. 2018; 20(2):197-207. PMC: 6007301. DOI: 10.5853/jos.2017.02901. View

16.

Wu S, Sena E, Egan K, Macleod M, Mead G . Edaravone improves functional and structural outcomes in animal models of focal cerebral ischemia: a systematic review. Int J Stroke. 2013; 9(1):101-6. DOI: 10.1111/ijs.12163. View

17.

Cook D, Tymianski M . Nonhuman primate models of stroke for translational neuroprotection research. Neurotherapeutics. 2012; 9(2):371-9. PMC: 3337022. DOI: 10.1007/s13311-012-0115-z. View

18.

Li R, Huang C, Chen J, Guo Y, Tan S . The role of uric acid as a potential neuroprotectant in acute ischemic stroke: a review of literature. Neurol Sci. 2015; 36(7):1097-103. DOI: 10.1007/s10072-015-2151-z. View

19.

Waring W, Webb D, Maxwell S . Systemic uric acid administration increases serum antioxidant capacity in healthy volunteers. J Cardiovasc Pharmacol. 2001; 38(3):365-71. DOI: 10.1097/00005344-200109000-00005. View

20.

Macleod M, van der Worp H, Sena E, Howells D, Dirnagl U, Donnan G . Evidence for the efficacy of NXY-059 in experimental focal cerebral ischaemia is confounded by study quality. Stroke. 2008; 39(10):2824-9. DOI: 10.1161/STROKEAHA.108.515957. View